Communiqués Clarity Pharmaceuticals Ltd

Actions

CU6

AU0000165375

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:10:31 21/08/2026			Varia. 5j.	Varia. 1 janv.
2,480 ^AUD	-5,34 %		-5,70 %	-26,63 %

05/08	Clarity Pharmaceuticals fait le point sur l'essai SECuRE pour le dosage de 8 GBq de 67Cu-SAR-bisPSMA	CI
05/08	Clarity Pharmaceuticals : deux nouveaux patients en réponse complète dans un essai contre le cancer de la prostate ; l'action bondit de 14 %	MT

Communiqués

11/08	Bell Potter rates CU6 as Speculative Buy	AQ
12/08/25	Bell Potter rates CU6 as Speculative Buy	AQ
18/07/25	Clarity Pharmaceuticals - Co-PSMA trial, Recruitment successfully completed	AQ
16/06/25	Sabre Topline Results Cu 64 Sar Bombesin Is Effective In Detecting Prostate Cancer Recurrence In Patients With Negative Soc Imaging	AQ
29/01/25	Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences	AQ
09/10/24	Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx	AQ
23/08/24	Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA	AQ
30/11/23	Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort	AQ
27/10/23	Clarity and PSI kick off SAR-bisPSMA Phase III	AQ
04/10/23	Clarity Pharmaceuticals - First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial	AQ
28/08/23	Clarity Pharmaceuticals - First participant treated in the highest dose cohort of neuroblastoma trial	AQ
28/08/23	First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial	AQ
25/07/23	Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial	AQ
05/07/23	Clarity Pharmaceuticals - Positive guidance from US FDA on Cu-64 SAR-bisPSMA Phase III trial in prostate cancer	AQ
29/06/23	Clarity establishes a US Center of Excellence for Targeted Copper Theranostics	AQ
21/06/23	Clarity commences COMBAT theranostic prostate cancer trial in the US	AQ
06/07/22	Clarity Pharmaceuticals : Application for quotation of securities - CU6	PU
09/06/22	Clarity Pharmaceuticals : Governance & Trading Policy Update	PU
01/06/22	Clarity Pharmaceuticals : Notification regarding unquoted securities - CU6	PU
21/04/22	Clarity Pharmaceuticals : Application for quotation of securities - CU6	PU
14/04/22	Clarity Pharmaceuticals : Application for quotation of securities - CU6	PU
02/03/22	Clarity Pharmaceuticals : - Investor Presentation 03-03-2022	PU
28/02/22	Clarity Pharmaceuticals : Half Yearly Report	PU